SMARTPTDRUGS

Fluorescent nanocrystals for activation and delivery of platinum drugs

Coordinatore	THE UNIVERSITY OF EDINBURGH    more  Organization address address: OLD COLLEGE, SOUTH BRIDGE city: EDINBURGH postcode: EH8 9YL contact info Titolo: Ms. Nome: Angela Cognome: Noble Email: send email Telefono: +44 1 316509024 Fax: +44 1 316514028
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	173˙240 €
EC contributo	173˙240 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2009-IEF
Funding Scheme	MC-IEF
Anno di inizio	2010
Periodo (anno-mese-giorno)	2010-10-01   -   2012-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	THE UNIVERSITY OF EDINBURGH  Organization address address: OLD COLLEGE, SOUTH BRIDGE city: EDINBURGH postcode: EH8 9YL contact info Titolo: Ms. Nome: Angela Cognome: Noble Email: send email Telefono: +44 1 316509024 Fax: +44 1 316514028	UK (EDINBURGH)	coordinator	173˙240.80

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Chemistry has made major contributions towards fighting cancer (Europe's major cause of death) by developing small molecules which can act as anticancer drugs. But despite extensive research efforts, defeating cancer is proving to be an enormous challenge. Inorganic chemistry has made its most important contribution in the form of platinum (Pt) complexes, which provide highly effective chemotherapy for testicular, ovarian, neck, cervical and esophageal cancers. Drug resistance and toxic side effects means that there are many occasions when Pt-based treatment must be discontinued and limit the ability of Pt drugs to cure other forms of cancer such as the more common colon and breast cancers. The problem is that the drugs are not ‘smart’ – they are not capable of identifying cancer cells and they react with a wide range of molecules. Another significant limitation is that it is not possible to control when and where they exert cytotoxicity. Here we propose a novel methodology to make: 1) Pt complexes capable of identifying cancer cells, 2) Pt drugs with a built-in security device –a switch which we can turn on externally to make the Pt drug active only when it reaches the tumour.'